ArticleJCO oncology advances2025

SWOG 2308: Randomized Phase III Study of Mosunetuzumab Versus Rituximab for Low-Tumor Burden Follicular Lymphoma.

Nilanjan Ghosh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.